VANCOUVER, Sept. 23 /CNW/ - Angiotech Pharmaceuticals, Inc. (“Angiotech”) (NASDAQ: ANPI, TSX: ANP), a global specialty pharmaceutical and medical device company, today announced that it has terminated its previously announced tender offer (the “Tender Offer”) for its outstanding Senior Floating Rate Notes Due 2013 (CUSIP No. 034918AF9) (the “First Priority Notes”), and its outstanding 7.75% Senior Subordinated Notes Due 2014 (CUSIP No. 034918AC6) (the “Second Priority Notes” and collectively with the First Priority Notes, the “Notes”). None of the Notes were purchased in the Tender Offer and all Notes previously tendered and not withdrawn will be promptly returned to their respective holders.
